Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2017
Price : $35 *
At a glance
- Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
- Indications Thyroid cancer
- Focus Diagnostic use
- Acronyms iTEP-CMT
- 17 Jan 2017 Status changed from recruiting to completed.
- 09 May 2016 Planned number of patients changed from 24 to 28.
- 24 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.